Logo

Hey, FDA, If You're Not Busy with Other Things...

May 02, 2008

Following the passage of GINA by US Congress, the Wall Street Journal reports that "a federal advisory panel called for tougher government oversight of the burgeoning genetic-testing business, warning that tests are being marketed with little evidence about their usefulness." (Now there's a shock.) The committee says all genetic lab tests should have to undergo stringent evaluation by FDA.

 

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.